Inhibition of Enhancer of Zeste Homolog 2 alleviates oxidative stress, inflammation and barrier damage of human corneal epithelial cells
Experimental Eye Research · 2026
DOI: 10.1016/j.exer.2025.110709 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental Eye Research, 2026. Verfasst von Sarah Adriana Scuderi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres, 31, 98166,…. Hauptthemen laut MEDLINE: Oxidative Stress, Epithelium, Corneal, Enhancer of Zeste Homolog 2 Protein, Dry Eye Syndromes. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
Dry Eye Disease (DED) is a multifactorial condition characterized by tear film instability, ocular surface inflammation, epithelial barrier dysfunction, and oxidative stress (OS). Recent studies have identified Enhancer of Zeste Homolog 2 (EZH2) as an important contributor to ocular surface diseases by promoting inflammation and epithelial dysfunction. Based on these findings, this study investigated the potential therapeutic effects of GSK343, a selective EZH2 inhibitor, in mitigating DED-associated pathological processes using in vitro models. Our findings demonstrated that low concentrations of GSK343 (1, 3 and 5 μM) did not compromise human corneal epithelial (HCE) cell viability and enhanced wound healing, suggesting its role in promoting epithelial regeneration. In H2O2-induced DED model, GSK343 pretreatment significantly restored HCE cell viability following H2O2-induced damage, reduced reactive oxygen species (ROS) levels and upregulated the expression of antioxidant enzymes as HO-1 and MnSOD, indicating a protective effect against OS. Additionally, GSK343 restored tight junction proteins (ZO-1 and occludin), reducing permeability and maintaining barrier integrity. In TNFα-induced DED model, GSK343 restored HCE cell viability and decreased the levels of pro-inflammatory cytokines IL-1β, TNFα, IL-6, and IL-17. Furthermore, GSK343 decreased the number of apoptotic cells and p53 positive cells, highlighting its protective properties. These findings suggest that GSK343 exerts anti-inflammatory, antioxidant, and epithelial-protective effects in DED models, suggesting EZH2 inhibition as a potential therapeutic strategy for DED management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres, 31, 98166, Messina, ME, Italy.
- Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Via Consolare Valeria 1, 98125, Messina, Italy.
- Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres, 31, 98166, Messina, ME, Italy. Electronic address: eesposito@unime.it.
Zitieren
APA
Scuderi, S. A., Palermo, N., Cucinotta, L., Mannino, D., Esposito, E., & Paterniti, I. (2026). Inhibition of Enhancer of Zeste Homolog 2 alleviates oxidative stress, inflammation and barrier damage of human corneal epithelial cells. Experimental Eye Research. https://doi.org/10.1016/j.exer.2025.110709
Vancouver
Scuderi SA, Palermo N, Cucinotta L, Mannino D, Esposito E, Paterniti I. Inhibition of Enhancer of Zeste Homolog 2 alleviates oxidative stress, inflammation and barrier damage of human corneal epithelial cells. Experimental Eye Research. 2026. doi:10.1016/j.exer.2025.110709
BibTeX
@article{Scuderi2026,
author = {Scuderi, Sarah Adriana and Palermo, Nicoletta and Cucinotta, Laura and Mannino, Deborah and Esposito, Emanuela and Paterniti, Irene},
title = {Inhibition of Enhancer of Zeste Homolog 2 alleviates oxidative stress, inflammation and barrier damage of human corneal epithelial cells},
journal = {Experimental Eye Research},
year = {2026},
doi = {10.1016/j.exer.2025.110709}
}
EUVIMED